title: Relationship between DNA repair gene XPD751 single-nucleotide polymorphisms and prognosis of colorectal cancer.
abstract: We examined the relationships between single-nucleotide polymorphisms (SNPs) in the DNA repair gene XPD751 and the efficacy and time to disease progression (TTP) in colorectal cancer patients after platinum-based chemotherapy. Ninety-eight patients diagnosed with advanced colorectal cancer were subjected to oxaliplatin and 5-fluorouracil combination therapy. DNA was extracted from venous blood before chemotherapy. Polymerase chain reaction-restriction fragment length polymorphism analysis was used to detect XPD751 SNPs. The relationship between genotypes and prognosis was compared. The frequencies of the XPD751 Lys/Lys, Lys/Gln, and Gln/Gln genotypes were 76 (77.55%), 17 (17.35%), and 5 (5.10%), respectively. The efficiency of XPD751 Lys/Lys, Lys/Gln and Gln/Gln genotypes were 50.00, 29.41, and 20%, respectively. The efficiency rate between XPD751 Lys/Lys and Lys/Gln showed a significant difference (c² = 4.04, P < 0.05). After adjusting for gender, age, and metastasis location, chemotherapy failure in patients carrying XPD751 Lys/Gln was 3.404-fold higher than in patients carrying the Lys/Lys genotype. Median TTP was 304 days (10.1 months) and median TTP in patients with XPD751 Lys/Lys and ≥1 Gln genotype was 340 and 87 days. After comparing TTP in patients carrying Lys/Lys and patients carrying ≥1 Gln, the difference was significant. SNPs in the DNA repair gene XPD751 may be associated with oxaliplatin and 5-fluorouracil chemotherapy sensitivity in colorectal cancer patients. These polymorphisms may be associated with TTP in patients with advanced colorectal cancer after first-line chemotherapy of oxaliplatin. XPD751 SNPs may be predictive factors of prognosis in colorectal cancer patients receiving oxaliplatin and 5-fluorouracil chemotherapy.
authors.affiliation: First Affiliated Hospital of Medical University, Dalian, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Dong
authors.affiliation: First Affiliated Hospital of Medical University, Dalian, China.
authors.forename: J W
authors.initials: JW
authors.lastname: Liu
authors.affiliation: First Affiliated Hospital of Medical University, Dalian, China.
authors.forename: Y J
authors.initials: YJ
authors.lastname: Gao
authors.affiliation: First Affiliated Hospital of Medical University, Dalian, China.
authors.forename: T
authors.initials: T
authors.lastname: Zhou
authors.affiliation: First Affiliated Hospital of Medical University, Dalian, China dlchenyamin@126.com.
authors.forename: Y M
authors.initials: YM
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D004260:DNA Repair / Q000235:genetics; D018450:Disease Progression; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D051759:Xeroderma Pigmentosum Group D Protein / Q000235:genetics*
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D051759:Xeroderma Pigmentosum Group D Protein; C497292:ERCC2 protein, human; D005472:Fluorouracil